Mesoblast Limited
NASDAQ:MESOBiotechnology
+$0.26 today
- Market cap
- $1.51B
- Beta
- 0.79
- P/E (TTM)
- -23.6
- EPS (TTM)
- -$0.06
Volume 0.13M
Average 0.21M
MESO Net Income
Bottom-line profit after all expenses, interest, and taxes.
Mesoblast LimitedNASDAQ: MESO
Net Income · Q4 FY2026 · quarter ended Jun 2026
Net income remains negative
Q4 FY2026 net income was -$8.67M, compared with -$27.1M a year earlier. Trailing-twelve-month net income was -$57.5M.
Context
- Net income amounted to 47.8% of revenue in FY2026, down 546.1 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2026 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$25.99M (+55.0%) for the fiscal year ending Jun 2027, a step up from the +43.5% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$8.67M+0.0% QoQ
- Last fiscal yearJun 2026
- -$57.76M+43.5% YoY
- LTMJun 2026
- -$57.5M+43.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +68.0% | +51.0% | -17.0 pp |
| 1 year | +43.5% | +55.0% | +11.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2026
- (57.76M) USD
- Year-over-year change
- +43.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | (57.76M) | +43.5% |
| FY2025 | 2025-06-30 | (102.14M) | -16.1% |
| FY2024 | 2024-06-30 | (87.96M) | -7.4% |
| FY2023 | 2023-06-30 | (81.89M) | +10.4% |
| FY2022 | 2022-06-30 | (91.35M) | — |
Net Income vs competitors
How MESO compares with its peers on the latest reported figures
- MESO's LTM Jun 2026 net income of -$57.5M is the 2nd highest of the 6 companies compared; the peer median is -$91.71M.
- Its year-over-year change of +43.7% is the 2nd highest of 6, against a peer median of -58.4%.
- Net income amounts to 47.8% of revenue for MESO, versus a peer median of 389.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | -$215K | +99.9% | — | 0.0% | |
| LTM Jun 2026 | -$57.5M | +43.7% | — | 47.8% | |
| LTM Mar 2026 | -$64.21M | -296.2% | — | 434.4% | |
| LTM Dec 2025 | -$91.71M | -58.4% | — | 345.4% | |
| LTM Mar 2026 | -$114.59M | -108.1% | — | — | |
| LTM Mar 2026 | -$129.91M | +26.1% | — | 2056.8% | |
| Peer median (excluding MESO) | -$91.71M | -58.4% | — | 389.9% | |
Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 10.21M | 7.5M | 5.9M | 17.2M | 120.79M |
| Cost of Revenue | 63.57M | 54.92M | 41.07M | 5.13M | 19.21M |
| Gross Profit | (53.36M) | (47.42M) | (35.17M) | 12.07M | 101.58M |
| Gross Margin | -522.6% | -632.2% | -595.9% | 70.2% | 84.1% |
| Research & Development | 32.82M | 27.19M | 25.35M | 34.81M | 97.94M |
| Selling, General & Admin | 57.97M | 53.11M | 23.63M | 39.31M | 55.13M |
| Operating Expenses | 90.79M | 76.79M | 48.98M | 74.51M | 153.08M |
| Depreciation & Amortization | 4.38M | 4.11M | 1.9M | 6.4M | 8.62M |
| EBITDA | (76.57M) | (58.55M) | (56.08M) | (73.66M) | (42.88M) |
| EBITDA Margin | -749.9% | -780.6% | -950.1% | -428.3% | -35.5% |
| Operating Income | (80.57M) | (69.29M) | (84.15M) | (62.44M) | (51.5M) |
| Operating Margin | -789.1% | -923.7% | -1425.7% | -363.1% | -42.6% |
| Interest Income | 0 | 831K | 1.82M | 3.55M | 3.93M |
| Interest Expense | 17.29M | 19.44M | 20.66M | 22.93M | 23.95M |
| Other Income / Expenses | (10.48M) | (12.81M) | (4M) | (39.37M) | (5.64M) |
| Income Before Tax | (91.59M) | (82.1M) | (88.15M) | (101.81M) | (57.14M) |
| Pre-Tax Margin | -896.9% | -1094.5% | -1493.5% | -592.0% | -47.3% |
| Income Tax Expense | (239K) | (212K) | (191K) | 330K | 615.74K |
| Net Income | (91.35M) | (81.89M) | (87.96M) | (102.14M) | (57.76M) |
| Net Margin | -894.6% | -1091.7% | -1490.3% | -593.9% | -47.8% |
| EPS (Basic) | (1.30) | (0.98) | (0.89) | (0.84) | (0.45) |
| EPS (Diluted) | (1.30) | (0.98) | (0.89) | (0.84) | (0.45) |
| Weighted Avg Shares | 68.27M | 83.77M | 98.67M | 120.78M | 129.49M |
| Weighted Avg Shares (Diluted) | 68.29M | 83.93M | 98.67M | 120.78M | 129.49M |
Mesoblast Limited
NASDAQ:MESO
Intrinsic Alpha fair value
Locked
Current Price
$11.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.